Dexcom 

$74.65
332
+$2.29+3.16% Friday 20:00

统计数据

当日最高
74.73
当日最低
72.51
52周最高
142
52周最低
62.34
成交量
3,122,863
平均成交量
9,517,941
市值
29.91B
市盈率
47.25
股息收益率
-
股息
-

即将到来

收益

24Oct已确认
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
0.14
0.26
0.38
0.5
预期每股收益
0.435085
实际每股收益
N/A

人们还关注

此列表基于关注DXCM的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

分析师评级

108$平均价格目标
最高估值为 $161。
来自过去6个月内的 15 个评级。这不是投资建议。
买入
67%
持有
33%
卖出
0%

关于

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
首席执行官
Kevin Sayer
员工
9500
国家
US
ISIN
US2521311074
WKN
000A0D9T1

上市公司